1
|
Cai T, Cui Y, Yu S, Li Q, Zhou Z, Gao Z. Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Am J Mens Health 2020; 14:1557988320905407. [PMID: 32274957 PMCID: PMC7153190 DOI: 10.1177/1557988320905407] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Revised: 01/05/2020] [Accepted: 01/13/2020] [Indexed: 12/16/2022] Open
Abstract
Studies reported that Serenoa repens was effective in relieving lower urinary tract symptoms (LUTS). This article carried out a systematic review and meta-analysis to compare Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia (BPH) after at least 6-month treatment cycle. Four studies involving 1,080 patients (543 in the Serenoa repens group and 537 in the tamsulosin group) were included in the meta-analysis. The results were as follows: compared with tamsulosin, Serenoa repens had a same effect in treating BPH in terms of International Prostate Symptom Score (IPSS) (mean difference [MD] 0.63, 95% confidence interval [CI] [-0.33, 1.59], p = 0.20), quality of life (QoL) (MD 1.51, 95% CI [-1.51, 4.52], p = 0.33), maximum flow rate (Qmax) (MD 0.27, 95% CI [-0.15, 0.68], p = 0.21), postvoid residual volume (PVR) (MD -4.23, 95% CI [-22.97, 14.44], p = 0.65), prostate-specific antigen (PSA) (MD 0.46, 95% CI [-0.06, 0.97], p = 0.08) with the exception of prostate volume (PV) (MD -0.29, 95% CI [-0.41, -0.17], p < 0.00001). For side effects, Serenoa repens was well tolerated compared with tamsulosin especially in ejaculation disorders (odds ratio [OR] = 12.56, 95% CI [3.83, 41.18], p < 0.0001) and decreased libido (OR = 5.40; 95% CI [1.17, 24.87]; p = 0.03). This study indicated that Serenoa repens had the same effect in treating BPH compared with tamsulosin in terms of IPSS, QoL, and PVR after at least 6-month treatment cycle, however, the latter had a greater improvement in PV compared with the former. And Serenoa repens did not increase the risk of adverse events especially with respect to ejaculation disorders and libido decrease.
Collapse
Affiliation(s)
- Tong Cai
- Binzhou Medical University, Yantai, Shandong, China
- Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
- Tong Cai, Yuanshan Cui, and Shaoxia Yu contributed equally to this work as co-first author
| | - Yuanshan Cui
- Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
- Department of Urology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
- Tong Cai, Yuanshan Cui, and Shaoxia Yu contributed equally to this work as co-first author
| | - Shaoxia Yu
- Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
- Tong Cai, Yuanshan Cui, and Shaoxia Yu contributed equally to this work as co-first author
| | - Qian Li
- Department of Research, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
| | - Zhongbao Zhou
- Binzhou Medical University, Yantai, Shandong, China
- Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
| | - Zhenli Gao
- Binzhou Medical University, Yantai, Shandong, China
- Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
| |
Collapse
|
2
|
Wang T, Wang L, Liang Y, Ju J, Cai Y, Zhang J, Zhen H, Liu Y, Tang X, Wang J, Liu J. Effect of α-receptor blockers on lower urinary tract symptoms, sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia. Exp Ther Med 2017; 14:587-592. [PMID: 28672971 PMCID: PMC5488476 DOI: 10.3892/etm.2017.4518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 05/17/2017] [Indexed: 02/06/2023] Open
Abstract
The purpose of the present study was to compare the effectiveness of two common α1-receptor blockers, alfuzosin and tamsulosin, on lower urinary tract symptoms, sexual function, and quality of life in young and middle-aged people with benign prostatic hyperplasia. We recruited 80 young and middle-aged patients with benign prostatic hyperplasia and divided them into two groups that received either the non-selective α1-receptor blocker alfuzosin or the selective α1A-receptor blocker tamsulosin for 18 consecutive days. After intervention, maximum urinary flow, bladder compliance, maximum detrusor pressure, maximum urethral pressure, 72 h urination frequency and urination frequency at night, average urinary volume, residual urinary volume, urinary symptom distress score were significantly better in the tamsulosin group than in the alfuzosin group. Also, sperm density, sperm motility, sperm activity, and sperm DNA fragmentation index were significantly better in the tamsulosin group compared to the alfuzosin group. Finally, international index of erectile function-5 scores, increased libido and erection, retrograde ejaculation, and the quality of life were significantly better in the tamsulosin group compared to the alfuzosin group. Overall, tamsulosin effectively relieved the lower urinary tract symptoms, improved semen quality, and increased sexual life and quality of life in young and middle-aged patients with benign prostatic hyperplasia.
Collapse
Affiliation(s)
- Tongqing Wang
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Lei Wang
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Yalin Liang
- Department of Nephrology, Zhengzhou Seventh People's Hospital, Zhengzhou, Henan 450000, P.R. China
| | - Jiechang Ju
- Department of Andrology, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Yi Cai
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Jie Zhang
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Hongtao Zhen
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Yaolei Liu
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Xiaolong Tang
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Jizheng Wang
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| | - Jian Liu
- Department of Urology Ward One, Zhengzhou Central Hospital Affiliated to the Zhengzhou University, Zhengzhou, Henan 450007, P.R. China
| |
Collapse
|